Posted by Michael Wonder on 17 Jun 2024
Bavarian Nordic completes BLA submission to US FDA for its Chikungunya vaccine candidate
17 June 2024 - First regulatory submission completed for CHIKV VLP seeking approval of the vaccine candidate for immunisation against chikungunya virus infection in individuals 12 years of age and older.
Bavarian Nordic today announced the completion of the rolling submission process which was initiated in April 2024 with the U.S. FDA for a biologics license application for the licensure of its CHIKV VLP vaccine candidate for immunisation against chikungunya virus infection in individuals 12 years of age and older.
